Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Naloxone (Narcan ® ) treatment in depression: Clinical observations and effects on CSF endorphins and monoamine metabolites

Naloxone (Narcan ® ) treatment in depression: Clinical observations and effects on CSF endorphins... 213 54 54 1 1 Lars Terenius Agneta Wahlström Hans Ågren Department of Medical Pharmacology University of Uppsala Uppsala Department of Psychiatry University Hospital Uppsala Box 573 S-751 23 Uppsala Sweden Abstract Various dysphoric states are seen both in mood depression and on taking opiates. On the hypothesis that opiate antagonists would alter mood level, naloxone (Narcan ® ), 0.4–0.8 mg t.i.d., was given to five depressed patients in six trials for a duration of 6–12 days. The CSF endorphin and monoamine metabolite content was analyzed before and after naloxone treatment. We observed no positive effect on mood level. However, an abrupt worsening of symptoms was noted in two cases on discontinuation of treatment. Decreasing values of endorphin Fraction I as a result of treatment was noted as a general trend. Fraction II, although elevated, showed no distinct trend. 5HIAA increased in four of the six trials. The results suggest that naloxone treatment changes endorphin and serotonin activity, though not to a clinically observable extent. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Psychopharmacology Springer Journals

Naloxone (Narcan ® ) treatment in depression: Clinical observations and effects on CSF endorphins and monoamine metabolites

Loading next page...
 
/lp/springer-journals/naloxone-narcan-treatment-in-depression-clinical-observations-and-S1CjUaWQA3

References (9)

Publisher
Springer Journals
Copyright
Copyright © 1977 by Springer-Verlag
Subject
Biomedicine; Pharmacology/Toxicology; Psychiatry
ISSN
0033-3158
eISSN
1432-2072
DOI
10.1007/BF00426537
Publisher site
See Article on Publisher Site

Abstract

213 54 54 1 1 Lars Terenius Agneta Wahlström Hans Ågren Department of Medical Pharmacology University of Uppsala Uppsala Department of Psychiatry University Hospital Uppsala Box 573 S-751 23 Uppsala Sweden Abstract Various dysphoric states are seen both in mood depression and on taking opiates. On the hypothesis that opiate antagonists would alter mood level, naloxone (Narcan ® ), 0.4–0.8 mg t.i.d., was given to five depressed patients in six trials for a duration of 6–12 days. The CSF endorphin and monoamine metabolite content was analyzed before and after naloxone treatment. We observed no positive effect on mood level. However, an abrupt worsening of symptoms was noted in two cases on discontinuation of treatment. Decreasing values of endorphin Fraction I as a result of treatment was noted as a general trend. Fraction II, although elevated, showed no distinct trend. 5HIAA increased in four of the six trials. The results suggest that naloxone treatment changes endorphin and serotonin activity, though not to a clinically observable extent.

Journal

PsychopharmacologySpringer Journals

Published: Jan 1, 1977

There are no references for this article.